AgroSpheres Inc. Overview
AgroSpheres is a ten-year-old agricultural biotechnology company that grew out of undergraduate research at the University of Virginia. Its core asset is AgriCell, a patented fermentation-based platform in which engineered microbes both produce and encapsulate an active ingredient in a biodegradable cellular shell. The encapsulation protects fragile actives — RNA, peptides, plant extracts and small molecules — from ultraviolet light, heat and moisture, and releases them in a controlled way, which the company says allows lower doses and multi-year shelf life. AgroSpheres monetizes the platform in two ways: its own biorational products, beginning with the thyme-oil biofungicide FUN-THYME sold exclusively through Wilbur-Ellis, and co-development programs with crop protection majors FMC and BASF built around RNA-based bioinsecticides. With a first commercial fermentation plant opened in April 2026 and two RNA candidates entering global field trials in September 2026, the company is transitioning from platform developer to early commercial manufacturer, though it remains small, loss-profile undisclosed and partner-dependent.
What the company does. AgroSpheres develops and manufactures biological crop protection products. Its own description (company release, April 2026) is of a developer and manufacturer of biological crop protection solutions intended to replace chemicals and microplastics on US farms, built on the AgriCell platform, with products positioned as safe for pollinators, workers and the environment. Its stated mission is to transform agriculture through reliable and affordable biobased solutions, and its tagline is "a future built by nature's technologies" (company website).
Technology. AgriCell is a one-step fermentation process: an engineered microbe produces a small spherical shell and loads the active ingredient inside it in the same step, avoiding separate synthesis and formulation stages (company website; C&EN, Nov 2024). The shell shields the payload from UV, heat and moisture and is engineered for controlled, targeted release (company release, 17 Sep 2026). The Series B announcement in 2022 also referenced a second patented technology, AgriShell, and the ability to embed proteins on the particle surface for targeting.
Business model. At the October 2022 Series B, the company described three pillars:
Revenue model mix. The split between product sales, collaboration income and grants is not publicly disclosed. Preqin characterizes revenue as arising from sales of biological products to producers and distributors; PitchBook, as shown on an investor profile, has tagged the company as "generating revenue".
Value chain position. AgroSpheres sits upstream as a technology originator and active/formulation manufacturer. It does not sell directly to growers at scale; market access is through a distributor (Wilbur-Ellis, about 120 retail locations) and through the global commercial organizations of FMC and BASF for pipeline products.
Customers and end-markets. End users are specialty crop growers — grapes, berries, apples, cherries, tomatoes and almonds for FUN-THYME — in conventional, organic and integrated programs. Pipeline bioinsecticides target lepidopteran pests in the United States, Brazil and Asia.
Independent characterization. AgroSpheres is best understood as a delivery-and-manufacturing platform company with one early commercial product and a partner-funded pipeline, not yet a scaled crop protection business. Its strategic value lies in solving the stability and cost problems that have limited sprayable RNA and other fragile biologicals. Commercial proof remains at an early stage: the company speaks of being on the way to protecting tens of thousands of acres, a very small footprint in the context of US specialty crops.
Strategy
There is no annual report or investor day. Strategy is inferred from releases and interviews.
Recurring themes.
-
Make biologicals reliable and affordable — closing the performance and shelf-life gap with synthetic chemistry through encapsulation.
-
Platform breadth — one manufacturing technology applied to RNA, peptides, plant extracts and small molecules.
-
Partner-led global reach — own products through distribution; novel biomolecules through majors with global regulatory and commercial infrastructure.
-
Domestic biomanufacturing — onshoring fermentation capacity and positioning against reliance on imported chemical ingredients.
-
Microplastic and chemical replacement — a biodegradable alternative to polymer microencapsulation.
Initiatives in the last 24 months.
Financial targets. None published. The only quantified targets are the Virginia investment and jobs commitment and the aspiration to scale capacity from hundreds of thousands to millions of treated acres. A 2023 interview stated an aim to have a first product approved and in market by end-2024; the actual launch was June 2025, a slip of about six months.
ESG commitments. No formal targets; sustainability is embedded in the product thesis.
Products & Services
Platform technologies
| Offering | Description | Capabilities claimed | Status |
|---|---|---|---|
| AgriCell | Fermentation-derived biodegradable encapsulation in which the microbe produces and loads the active in one step | Protection from UV, heat and moisture; controlled and targeted release; dose reduction; multi-year shelf life; compatible with RNA, peptides, plant extracts and small molecules | Commercial (first product launched June 2025); patented |
| AgriShell | Second encapsulation technology named in 2022 materials | Paired with AgriCell for long shelf-life biological pesticides | Referenced in 2022; little later disclosure |
| Biomodality platform | Discovery approach for biomolecules acting on specific biological pathways in a target pest | Precision, resistance management, reduced impact on beneficial insects | Feeds the FMC and BASF programs |
Commercial product
| Attribute | FUN-THYME |
|---|---|
| Category | Broad-spectrum biofungicide |
| Active | Thyme oil bioactives, AgriCell-encapsulated |
| Mode of action | Membrane disruption (BM01 classification) |
| Target crops | Grapes, berries, apples, cherries, tomatoes, almonds |
| Target customer | Specialty crop growers; conventional, organic and IPM programs |
| Certification | OMRI-listed |
| Use rate | One 2.5-gallon jug treats up to 20 acres |
| Launch | 24 June 2025 (US) |
| Registrations | California (March 2026) plus 15 other US states |
| Channel | Wilbur-Ellis, exclusive distribution; described as co-developed |
| Pricing | — |
| Evidence | Three years of field development; a 2025 California State University, Fresno study found no adverse effect on grape maturity, yield or wine sensory quality |
Pipeline
| Program | Partner | Target | Stage | Source |
|---|---|---|---|---|
| RNA-based bioinsecticide candidate 1 | FMC | Lepidopteran pests (e.g. fall armyworm, diamondback moth) | Global field trials (US, Brazil, Asia) from Sept 2026 | Company/FMC release, 17 Sep 2026 |
| RNA-based bioinsecticide candidate 2 | FMC | Lepidopteran pests | Global field trials from Sept 2026 | Same |
| Novel bioinsecticide on AgriCell-powered biomolecules | BASF | — | Development; stage not disclosed | Release, 25 Oct 2024 |
| Additional products | Unnamed crop protection companies | — | Development | Company release, Apr 2026 |
Services
Formulation-as-a-Service: applying AgriCell to third-party actives, including replacement of microplastic or solvent-based formulations. Individual engagements and pricing are not disclosed. The company states explicitly that it does not position itself as a contract manufacturer.
Financial Narrative
No audited or management financial statements are public. Revenue, profit, balance sheet, cash flow and ratio data are not publicly disclosed, and no estimates are offered. The tables are retained in the required format with blank cells.
Income statement:
Balance sheet and cash flow:
Ratios (ROE, ROA, ROIC, current ratio, leverage, coverage, turnover, cash conversion cycle) cannot be computed.
What is disclosed: funding history. The only quantitative financial series available is capital raised. Calendar years are used; 2020 is from an aggregator only; 2024 is the increment from USD 22 M to the USD 37 M final close.
Source conflicts on total funding. C&EN (Nov 2024) cites roughly USD 50 M, consistent with the table. Employbl shows about USD 52.9 M including grants. Tracxn shows USD 97.5 M, which appears to double-count Series B tranches. Seedtable and VCBacked show far lower totals. The approximately USD 50 M figure is the best supported.
Other disclosed financial markers. About USD 10 M invested in the Charlottesville region to date against a USD 25 M commitment by 2030; a USD 200,000 Commonwealth's Opportunity Fund grant; training support through the Virginia Jobs Investment Program; about USD 1 M in grants by 2019 from the NSF and Virginia Catalyst (Global AgInvesting).
Commentary. The capital pattern is typical of a platform agbiotech: small seed and Series A rounds to prove technology, a larger Series B timed to manufacturing build-out and first launch, and strategic money (FMC) arriving alongside a collaboration. The last disclosed raise closed in September 2024, and the company has since funded a commercial plant and a product launch. Cash runway is therefore the central unknown.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Balance Sheet
| Metric | CY2017 | CY2018 | CY2019 | CY2020 | CY2021 | CY2022 | CY2023 | CY2024 |
|---|---|---|---|---|---|---|---|---|
Disclosed equity raised in year (USD Mn) | 0.75 | 0 | 4.5 | 8.8 | 0 | 22 | 0 | 15 |
Cumulative disclosed equity (USD Mn) | 0.75 | 0.75 | 5.25 | 14.05 | 14.05 | 36.05 | 36.05 | 51.05 |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable — no listed shares |
Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B) | Not applicable; round valuations not publicly disclosed |
Analyst consensus | None — no sell-side coverage |
Dividend history and policy | None disclosed |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Balance Sheet (CY2022–CY2026)
| Metric | CY2022 | CY2023 | CY2024 | CY2025 | CY2026 |
|---|---|---|---|---|---|
Cumulative disclosed equity raised (USD Mn) | 36.05 | 36.05 | 51.05 | 51.05 | 51.05 |
Analyst Conclusions
Guidance and consensus. There is no management financial guidance and no analyst consensus. The only forward markers are operational: capacity expansion from hundreds of thousands to millions of treated acres, and USD 25 M of regional investment and 53 jobs by 2030.
Bull case
-
Platform validation by two majors, with the FMC program having cleared laboratory, greenhouse and small-plot stages against industry-standard chemistry before entering three-continent trials.
-
A real product in a real channel: FUN-THYME is registered in 16 states with California access and a low use rate supportive of grower economics.
-
Owned manufacturing in a capacity-constrained US fermentation market, giving control over cost and supply and a base for further partner programs.
Bear case
-
Commercial scale is unproven; tens of thousands of acres is a pilot-level footprint, and thyme oil is a crowded active.
-
Pipeline value is hostage to partner priorities and to regulatory approval of RNA actives in multiple jurisdictions, likely several years away.
-
Funding visibility is poor: two years since the last disclosed raise, during a period of heavy investment.
Catalysts and monitorables (next 12 months)
What can be assessed is strategic trajectory, and on that basis the past 18 months have been the most substantive in the company's history: a first product launched, California access obtained, a commercial fermentation plant commissioned, and two RNA candidates advanced into global field trials with FMC.
The underlying thesis is credible. Sprayable RNA and other fragile biologicals have been limited by cost and field stability, and a process that manufactures and encapsulates in a single fermentation step addresses both. The willingness of FMC and BASF to build programs on the platform, and of an established distributor to take exclusive rights to the first product, is meaningful third-party validation. The quality of the board and advisers is also well above what the company's size would predict.
Against that, the evidence of commercial traction is thin and self-reported. FUN-THYME is a sensible beachhead rather than a company-making product. The real value sits in the partnered insecticide pipeline, where timelines are long, economics undisclosed and control rests with partners. The absence of any announced financing since September 2024, set against a manufacturing build-out, makes capital adequacy the principal unresolved question.
On balance, AgroSpheres is a technically differentiated, well-sponsored platform company at an inflection point, with outcomes heavily dependent on 2026–2027 field trial data and on its next financing. For a counterparty assessing it as a partner, supplier or target, direct diligence on cash position, partner contract terms, patent scope and plant utilization is essential; none can be established from public sources.
SOURCES CONSULTED
-
AgroSpheres website (home, about, news) and press releases — Primary — Accessed 3 Oct 2026
-
AgroSpheres / FMC release on global field trials — Primary — 17 Sep 2026
-
AgroSpheres release on biomanufacturing facility — Primary — 15–16 Apr 2026
-
AgroSpheres / Wilbur-Ellis release on California approval — Primary — 17 Mar 2026
-
Business Wire: FUN-THYME launch — Primary — 24 Jun 2025
-
Virginia Bio: Series B final close; BASF partnership — Primary (reposted) — 30 Sep 2024; 25 Oct 2024
-
FMC Corporation release on collaboration — Primary — 9 May 2024
-
Series B release (BioBuzz, Global AgInvesting, AgriBusiness Global) — Primary (reposted) — Oct 2022
-
Ospraie Ag Science release; Fruit Growers News; Global AgInvesting interview — Primary / trade press — Aug–Sep 2019
-
US House Small Business Committee testimony of Mark Kester — Government record — 5 Oct 2017
-
Chemical & Engineering News start-up profile — Trade press — Nov 2024
-
UVA Darden news; CBS19 News; Manufacturing.net; iGrow News; HortiDaily; Global Agriculture; AgTechNavigator — Press — 2025–2026
-
CvilleBioHub company page — Regional directory — 2026
-
Preqin, Tracxn, Employbl, SP Edge, Seedtable, VCBacked, Motherbase, CB Insights, PitchBook — Aggregators (lower reliability; conflicts noted) — Various
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Background |
|---|---|---|
Payam Pourtaheri | Co-Founder and CEO | UVA biomedical engineering; previously COO; leads business development, operations, regulatory and IP strategy; board member of CvilleBioHub and Venture Central |
Ameer Shakeel | Co-Founder and CTO | UVA biomedical engineering; leads technology development, strategic collaborations and manufacturing expansion |
Dr. Prem Warrior | Chief Growth Officer | Former COO and board director at Valagro; former Senior Program Officer, Bill & Melinda Gates Foundation; former Senior Director of Global Research, Valent BioSciences |
Karen Warkentien | Director of Regulatory Affairs | Nearly four decades in pesticide regulation, starting at US EPA's Office of Pesticide Programs; BPIA subcommittee co-chair |
Board of Directors
| Director | Affiliation | Notes |
|---|---|---|
Carl Casale | Ospraie Ag Science | Investor director; led the 2019 Series A; former Monsanto CFO |
Dr. Robert (Robb) Fraley | Independent / industry | Former Monsanto EVP and CTO; World Food Prize Laureate |
Dr. Larry Page | Lewis & Clark AgriFood | Managing Director; joined October 2022; PhD in biochemistry, Washington University in St. Louis (not the Google co-founder) |
Payam Pourtaheri; Ameer Shakeel | Founders | Board seats presumed but not confirmed in public sources |
Competitive Landscape
Key Competitors
| Competitor | Area of overlap | Ownership | Relative positioning |
|---|---|---|---|
GreenLight Biosciences | Sprayable RNA; first US-approved foliar RNAi insecticide (Calantha, for Colorado potato beetle) | Private (taken private 2023) | Ahead on RNAi registration; cell-free RNA production rather than encapsulation |
Vestaron | Peptide bioinsecticides | Private | Commercial peptide products; competing novel mode of action for lepidoptera |
Invaio Sciences | Biological actives and delivery | Private | Well funded delivery platform |
Terramera | Botanical actives and delivery technology | Private | Earlier Ospraie-backed peer |
Pro Farm Group (formerly Marrone Bio) | Biofungicides, bioinsecticides | Bioceres Crop Solutions | Broad commercial biological portfolio |
Certis Biologicals | Biofungicides, bioinsecticides | Mitsui & Co. | Established specialty crop biologicals supplier |
Thyme oil fungicide brands (e.g. Thymox Control, Thyme Guard) | Direct active-ingredient competitors to FUN-THYME | Private | Unencapsulated thyme oil at conventional rates |
Vive Crop Protection | Delivery technology for actives | Private | Polymer-based delivery, not biodegradable cell-based |
Syngenta, Bayer, Corteva | In-house RNAi and biologicals programs | Public / state-owned | Vast resources; also potential partners |
RNAissance Ag, Trillium Ag, Genolution (AgroRNA) | RNA production and delivery | Private | Alternative low-cost RNA manufacturing approaches |
Peer Comparison FY2024
| Company | Revenue FY2024 | Growth |
|---|---|---|
FMC Corporation (partner and peer) | About USD 4.25 B | Negative |
Corteva Agriscience | About USD 16.9 B | Slightly negative |
BASF Agricultural Solutions (partner and peer) | About EUR 9.8 B | Slightly negative |



